Clinical trials in L'hospitalet De Llobregat – page 41

Study of Tarlatamab and Durvalumab compared to Durvalumab alone for patients with extensive stage small cell lung cancer

Study of Tarlatamab and Durvalumab compared to Durvalumab alone for patients with extensive stage small cell lung cancer

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Efficacy and Safety Evaluation of Tulisokibart in Moderate to Severe Hidradenitis Suppurativa: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy and Safety Evaluation of Tulisokibart in Moderate to Severe Hidradenitis Suppurativa: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study

Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study

Phase 1 Study of ADCT-901 in Patients with Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Antitumor Activity

Phase 1 Study of ADCT-901 in Patients with Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Antitumor Activity

Phase 3 Study of Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Metastatic NSCLC with PD-L1 TPS ≥50%

Phase 3 Study of Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Metastatic NSCLC with PD-L1 TPS ≥50%

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

A study testing how well zodasiran works and how safe it is for teenagers and adults with homozygous familial hypercholesterolemia

A study testing how well zodasiran works and how safe it is for teenagers and adults with homozygous familial hypercholesterolemia